JPMorgan downgraded Blueprint Medicines (BPMC) to Neutral from Overweight with a price target of $129, down from $130, after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right. The firm cites the deal for the downgrade with the expected close in Q3.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank
- Blueprint Medicines downgraded to Hold from Buy at Needham
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Blueprint Medicines downgraded to Neutral from Outperform at Wedbush